Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pak Fah Yeow International's Revenue for the
six
months ended in Dec. 2025 was HK$119.2 Mil. Pak Fah Yeow International's average Accounts Receivable for the
six
months ended in Dec. 2025 was HK$11.0 Mil.
Hence, Pak Fah Yeow International's Receivables Turnover for the
six
months ended in Dec. 2025 was 10.88.
Pak Fah Yeow International (HKSE:00239) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pak Fah Yeow International Receivables Turnover Related Terms
Pak Fah Yeow International Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International Receivables Turnover Chart
HKSE:00239 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International (HKSE:00239) has a Receivables Turnover of 10.88 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pak Fah Yeow International and its competitors. According to the industry distribution chart, Pak Fah Yeow International ranks #52 out of 949 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Pak Fah Yeow International's Receivables Turnover too high?
Pak Fah Yeow International's current Receivables Turnover is 10.88. The Drug Manufacturers industry median Receivables Turnover is 5.07. Pak Fah Yeow International's value of 10.88 is 114.6% above this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #52 out of 949 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pak Fah Yeow International has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #52 out of 949 companies for Receivables Turnover. This places Pak Fah Yeow International in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Pak Fah Yeow International's value of 10.88 is 114.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current Receivables Turnover of 10.88 is 114.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current Receivables Turnover is 10.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$2.20, compared to a current price of HK$2.45 — trading 11.4% above its estimated fair value. The current Receivables Turnover is 10.88 and 114.6% above the Drug Manufacturers industry median of 5.07. Pak Fah Yeow International's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current Receivables Turnover is 10.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.45 is trading 11.4% above its estimated GF Value™ of HK$2.20.
GuruFocus considers Pak Fah Yeow International to be Modestly Overvalued.
Key valuation signals for HKSE:00239:
Receivables Turnover: 10.88
GF Value™: HK$2.20 vs. price of HK$2.45 (11.4% above fair value)
Industry Position: 114.6% above the Drug Manufacturers median (#52 of 949)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
78GF Score
Get the complete analysis for HKSE:00239
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
